<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Curewell Capital 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=49271></link><description><![CDATA[Curewell Capital 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Sat, 25 Apr 2026 01:09:58 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2025/10/12_31017998_20251023134159_7779451439.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[Wilmington PharmaTech Continues Expansion with Significant Investment from Curewell Capital]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1021239</link><description><![CDATA[NEWARK, Del.--(Business Wire/Korea Newswire)--Wilmington PharmaTech (“WPT”), a U.S.-based specialty contract research, development, and manufacturing organization (CRDMO) focused on custom small molecule API development and manufacturing, today announced a majority investment by Curewell Capital (“Curewell”), a Los Angeles-based private equity firm focused on building industry-leading healt...]]></description><image><url><![CDATA[https://file.newswire.co.kr/data/datafile2/thumb/2025/10/31017998_20251023134730_9828187735.jpg]]></url></image><pubDate>Thu, 23 Oct 2025 14:10:00 +0900</pubDate></item><item><title><![CDATA[윌밍턴 파마텍, 큐어웰 캐피털의 대규모 투자 유치로 사업 확장 지속]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1021240</link><description><![CDATA[뉴어크, 델라웨어--(Business Wire/뉴스와이어)--맞춤형 저분자 원료의약품(API) 개발 및 생산에 주력하는 미국 기반 특수 의약품 위탁연구개발생산기관(CRDMO)인 윌밍턴 파마텍(Wilmington PharmaTech, 이하 ‘WPT’)이 큐어웰 캐피털(Curewell Capital, 이하 ‘큐어웰’)로부터 과반수 지분 투자를 유치했다고 발표했다. 큐어웰은 로스앤젤레스에 본사를 둔 사모펀드 회사로, 업계 선도적인 헬스케어 기업 구축에 주력한다. ...]]></description><pubDate>Thu, 23 Oct 2025 14:10:00 +0900</pubDate></item></channel></rss>